Treatment for Recurrent Ovarian Cancer—At First Relapse

Table 3

Phase III study results for platinum sensitive recurrent ovarian cancer.

	PTX/CBOCA (COOP)	PTX/CBOCA	GEM/CBOCA		PLO/CBOCA	PLO/CBOCA
	versus Pt combination	versus CBDCA	versus CBDCA		versus CBDCA	versus PTX/CBOCA
Dose (mg/m^2)	175–185/ AUC 5 (50–75)	175/AUC 5	1000/AUC 4		30/AUC 5	30/AUC 5
	versus AUC 5 (50–75)	versus AUC 5	versus AUC 5		versus AUC 5	versus 175/AUC 5
Author		González-Martín et al.	Pfisterer et al.		Alberts et al.	Pujiade-Lauraine et al.
	ICON4/ [6]	GEICO [7]	AGO OVAR, [8]		SWOG [9]	GClG [10]
Study group	AGO-OVAR2.2		NCIC CTG, EORTC GCG
Number of patients	392 versus 410	41 versus 40	178 versus 178		31 versus 30	466 versus 508
Response rate (%)	66 versus 54	75.6 versus 50.0^∗	47.2 versus 30.9^∗		52 versus 29	NA
PFS (months)	12 versus 9^∗	12.2 versus 8.4^∗	8.6 versus 5.8^∗		12 versus 8^∗	11.3 versus 9.4^∗
OS (months)	29 versus 24^∗	NA	18 versus 17.3		26 versus 18^∗	NA

PTX: paclitaxel; PT: cisplatin or carboplatin.
CBDCA: carboplatin; GEM: gemcitabine; PLD: pegylated Iiposomal doxorubicin.
PFS: progression free interval; PS: overall survival.
NA: not applicable.
∗Statistically significant.